Therma Bright’s AI-powered digital cough technology is being considered as a partner technology in a new clinical trial of a chronic cough drug Page 1

Toronto, Ontario–(Newsfile Corp. – August 16, 2024) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), a developer and investment partner in a broad range of advanced, proprietary diagnostic and medical device technologies, is pleased to announce that its AI-based Digital Cough Technology (DCT), with development partner AI4LYF, is currently being considered as a partnering technology for a novel, innovative, breakthrough clinical trial of a chronic cough drug in the U.S.

“We are pleased to hear from our development partners at AI4LFY that our AI-power DCT platform is in the top 10 for use in a U.S. clinical trial of a novel and innovative chronic cough medication with a leading pharmaceutical brand,” said Rob Fia, CEO of Therma Bright. “Our DCT solution and data collection platform are ideally positioned for clinical studies like this, enabling healthcare providers and epidemiologists to make more accurate and informed clinical decisions to quickly address the respiratory challenges of a patient or group of patients.”